CA/MG-ZYME CAPS (Calcium-Magnesium) – 240 Tablets
*** Please Login or Register with DC Nutrition to see Prices and Add To Cart. ***
Login | Create An Account / Register
CA/MG-Zyme is a source of calcium citrate and magnesium aspartate in a ratio of five parts of calcium to one part magnesium. Use it with muscle cramps, for long-term calcium supplementation, fever, increased secretions, autonomic imbalance, endocrine hyperactivity, low blood calcium, skin conditions such as itching and skin lesions, and for the excessive bleeding seen with heavy menses and nose bleeds.
Calcium citrate is the most easily absorbed form of calcium, where you will absorb almost 100%, as compared with most other forms where you will absorb only 5 to 8%. Magnesium aspartate is also very easily absorbed. My patients tell me they take this product and it never upsets their stomach or constipates them.
Use CA/MG-Zyme at two to three capsules, once or twice daily after meals. With fever or acute muscle cramps, you can use three capsules per hour until the problem abates; then begin to reduce the dosage.
The five to one ratio of calcium to magnesium is based on how calcium and magnesium should be found in relation to one another in the serum. This was also the advice generally given by the researchers Price, Lee and others. Years ago everybody felt that was the way it should be dosed in oral form, five parts of calcium to one part of magnesium.
PRODUCT DESCRIPTION
CA/MG-ZYME (240 Tablets)
Ca/Mg-Zyme™ supplies a supplemental source of calcium and magnesium in a tablet form. Calcium and magnesium are the most abundant intracellular cations, whose benefits are seen in multiple systems including the cardiovascular, nervous and musculoskeletal systems.* Ca/Mg-Zyme™ delivers 300 mg calcium citrate along with 60 mg magnesium citrate per 6 tablet serving.
Ingredients
Calcium (as calcium citrate), Magnesium (as magnesium citrate). Capsule shell (gelatin and water), cellulose and magnesium stearate (vegetable source).





Reviews
There are no reviews yet.